Kevin Tang and Tang Capital Management LLC, recognized as 10% owners of Boundless Bio, Inc. (NASDAQ:BOLD), have collectively acquired an additional $268,880 worth of common stock. These transactions occurred between June 30 and July 2, 2026, reflecting a calculated increase in their position within the clinical-stage biotechnology firm.
The acquisitions were executed at weighted-average prices ranging from $2.49 to $2.54 per share. This insider buying activity takes place as BOLD trades at $2.50, a level near its 52-week high of $2.79. The stock has demonstrated significant momentum, recording a 137% gain over the past year. Analytical assessments suggest the stock may be undervalued at these current levels, noting strong performance across multiple timeframes and a cash position that exceeds debt, despite the company's rapid cash burn rate.
On June 30, 2026, the reporting entities purchased 25,930 shares at a weighted-average price of $2.54. These shares were acquired through multiple transactions with prices ranging from $2.49 to $2.60. On the same day, an additional 100 shares were bought at $2.50 per share.
Further acquisitions were recorded on July 1, 2026, involving the purchase of 71,612 shares at a weighted-average price of $2.49. These transactions occurred at prices ranging from $2.46 to $2.50. The final reported transaction on July 2, 2026, involved the purchase of 9,821 shares at a weighted-average price of $2.49, with individual prices ranging from $2.47 to $2.50.
Following these acquisitions, Kevin Tang and Tang Capital Management LLC indirectly hold a total of 2,641,308 shares of Boundless Bio common stock. Kevin Tang serves as the sole manager of Tang Capital Management, LLC, which acts as the general partner for Tang Capital Partners, LP ("TCP") and Tang Capital Partners International, LP ("TCPI"). He is also the sole director and Chief Executive Officer of Tang Capital Partners III, Inc. ("TCP III") and Tang Capital Partners IV, Inc. ("TCP IV"), which are indirectly wholly owned by TCP. Mr. Tang holds a pecuniary interest in the shares beneficially held by these entities.
Concurrently, Boundless Bio has announced a definitive merger agreement with Serapha Bio, a clinical-stage biotechnology company. This all-stock transaction will result in a new entity operating under the Serapha Bio name, with pre-merger Boundless Bio stockholders owning approximately 3.7% of the combined company. The merger is expected to be completed soon, with the new entity trading on Nasdaq under the ticker symbol "AATD." Prior to the merger's completion, Boundless Bio plans to declare a cash dividend of approximately $44 to $48 million to its pre-merger stockholders.
Additionally, Boundless Bio held its annual meeting of stockholders, where James Christensen, Ph.D., and Jennifer Lew were elected as Class II directors, serving until the 2029 annual meeting. In another development, the company presented preclinical data on its lead therapy, BBI-940, at the American Association for Cancer Research Annual Meeting. This therapy is currently being evaluated in a Phase 1 trial for patients with specific types of advanced breast cancer.
Furthermore, Boundless Bio has agreed to terminate its lease for its San Diego laboratory and office space, with a payment of $10 million as consideration for the early termination. The lease, originally set to expire in 2034, will now end in May 2026. These recent developments highlight significant changes and strategic moves within the company.